Methods

Subjects
Male and female patients aged 60 years or over who had a respiratory tract infection were entered into the trial. To be included patients had to have at least one of the following symptoms of respiratory tract infection : cough, sputum, dyspnea, sore throat, pain on swallowing, rhinorrhea.
Exclusion criteria were treatment with systemic antibacterial agents for more than 72 h prior to enrollment in the study ; known hypersensitivity to fluoroquinolones ; known central nervous system disorders that might predispose to seizures or lower the seizure threshold ; the use of corticosteriods (prednisolone 10 Although there were no significant differences between the incidence of adverse events in the LVFX 300 mg once-daily group and the LVFX 100 mg threetimes-daily group ( 
